schliessen

Filtern

 

Bibliotheken

Safety of Alirocumab (A PCSK9 Monoclonal Antibody) from 14 Randomized Trials

Previous individual trials of alirocumab (a PCSK9 monoclonal antibody) showed significant low-density lipoprotein cholesterol reductions with overall treatment-emergent adverse event (TEAE) rates comparable with controls. This analysis evaluated safety data from 14 trials (4 phase 2 and 10 phase 3,... Full description

Journal Title: The American Journal of Cardiology 2016-12-15, Vol.118 (12), p.1805-1811
Main Author: Jones, Peter H
Other Authors: Bays, Harold E , Chaudhari, Umesh , Pordy, Robert , Lorenzato, Christelle , Miller, Kathryn , Robinson, Jennifer G
Format: Electronic Article Electronic Article
Language: English
Subjects:
Publisher: United States: Elsevier Inc
ID: ISSN: 0002-9149
Link: https://www.ncbi.nlm.nih.gov/pubmed/27729106
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: cdi_proquest_miscellaneous_1850780331
title: Safety of Alirocumab (A PCSK9 Monoclonal Antibody) from 14 Randomized Trials
format: Article
creator:
  • Jones, Peter H
  • Bays, Harold E
  • Chaudhari, Umesh
  • Pordy, Robert
  • Lorenzato, Christelle
  • Miller, Kathryn
  • Robinson, Jennifer G
subjects:
  • Abridged Index Medicus
  • Acute Coronary Syndrome - epidemiology
  • Aged
  • Analysis
  • Angina, Unstable - epidemiology
  • Antibodies, Monoclonal - adverse effects
  • Anticholesteremic Agents - adverse effects
  • Antilipemic agents
  • Atherosclerosis
  • Back Pain - chemically induced
  • Cardiology
  • Cardiovascular Medicine
  • Clinical Trials, Phase II as Topic
  • Clinical Trials, Phase III as Topic
  • Comorbidity
  • Confidence intervals
  • Coronary Disease - epidemiology
  • Coronary heart disease
  • Diabetes
  • Diabetes Mellitus, Type 2 - epidemiology
  • Drug dosages
  • Ezetimibe - adverse effects
  • FDA approval
  • Health aspects
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use
  • Hypercholesterolemia - drug therapy
  • Hypercholesterolemia - epidemiology
  • Influenza, Human - chemically induced
  • Low density lipoproteins
  • Medical colleges
  • Middle Aged
  • Monoclonal antibodies
  • Myocardial Infarction - epidemiology
  • Nasopharyngitis - chemically induced
  • Patients
  • Pruritus
  • Pruritus - chemically induced
  • Randomized Controlled Trials as Topic
  • Respiratory Tract Infections - chemically induced
  • Stroke (Disease)
  • Stroke - epidemiology
  • Studies
  • Urinary Tract Infections - chemically induced
ispartof: The American Journal of Cardiology, 2016-12-15, Vol.118 (12), p.1805-1811
description: Previous individual trials of alirocumab (a PCSK9 monoclonal antibody) showed significant low-density lipoprotein cholesterol reductions with overall treatment-emergent adverse event (TEAE) rates comparable with controls. This analysis evaluated safety data from 14 trials (4 phase 2 and 10 phase 3, 8 to 104 weeks; n = 5,234), in 2 pools according to control (placebo/ezetimibe). Overall, 3,340 patients received alirocumab (4,029 patient-years' exposure), 1,276 received placebo, and 618 received ezetimibe. Incidence of deaths, serious TEAEs, discontinuations because of TEAEs, and overall TEAEs were similar between alirocumab and control groups. Alirocumab was associated with a higher incidence of local injection site reactions (7.4% vs 5.3% with placebo; 3.1% vs 2.3% with ezetimibe), pruritus (1.3% vs 0.4% placebo; 0.9% vs 0.5% ezetimibe), and upper respiratory tract infection signs and symptoms (2.1% vs 1.1% placebo; 1.3% vs 0.8% ezetimibe). Incidence of musculoskeletal, neurologic, neurocognitive, ophthalmologic, hepatic events, and TEAEs related to diabetes/diabetes complications was similar between alirocumab and control groups. In a prespecified analysis of phase 3 studies, adjudicated major adverse cardiovascular events (coronary heart disease death, nonfatal myocardial infarction, ischemic stroke, and unstable angina requiring hospitalization) occurred in 1.8% alirocumab versus 2.6% placebo patients (hazard ratio 0.69, 95% confidence interval 0.43 to 1.11) and 2.8% alirocumab versus 1.5% ezetimibe patients (hazard ratio 1.4, 95% confidence interval 0.65 to 3.02). In conclusion, pooled safety data from 14 trials demonstrate that alirocumab is generally well tolerated with a favorable safety profile.
language: eng
source:
identifier: ISSN: 0002-9149
fulltext: no_fulltext
issn:
  • 0002-9149
  • 1879-1913
url: Link


@attributes
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
RANK2.6998782
LOCALfalse
PrimoNMBib
record
control
sourceidgale_opena
recordidTN_cdi_proquest_miscellaneous_1850780331
sourceformatXML
sourcesystemPC
galeidA472841623
sourcerecordidA472841623
originalsourceidFETCH-LOGICAL-1579t-8a1f695601056a5ce056b35ff94935b9e5fbcd5d54ba7bf65149b8d7608e3d330
addsrcrecordideNqNkk1v1DAQhiMEotvCTwBF4lIOGzxJ7NjigFYrPioWgWg5W_4YI68Se-tkkZZfX0e79NBLkQ-jsd730Yz9FsUrIBUQYO-2lRq2RiVb1bmtCK9IVz8pFsA7sQQBzdNiQQiplwJacVacj-M2twCUPS_O6q6rBRC2KDbXyuF0KKMrV71P0ewHpcvLVfljff1VlN9iiKaPQfXlKkxeR3t4W7oUhxLa8qcKNg7-L9ryJnnVjy-KZy4XfHmqF8WvTx9v1l-Wm--fr9arzRJoJ6YlV-CYoIwAoUxRg7nohjonWtFQLZA6bSy1tNWq047RvIHmtmOEY2ObhlwUV0du3GFQPqHcJT-odJBReWkDTlKrEXMnrRCMWE0NMK2YnhG0zUQujACKLLMuj6xdird7HCc5-NFg36uAcT9K4JR0nDQN_Ie0oS2pOZ8nfPNAuo37lJ9xVrVd2zAAkVXVUfVb9Sh9cHFKyuRjcfAmBnQ-36_aruYtsHrG0qPBpDiOCd394kDkHAu5ladYyDkWknCZY5F9r0_j7PWA9t71LwdZ8P4B2PhJTT6GPJHvH8V_OLoxf_ofj0mOxmMwaPPfmEna6B8h3AFW6dn2
sourcetypeOpen Access Repository
isCDItrue
recordtypearticle
pqid1847436119
display
typearticle
titleSafety of Alirocumab (A PCSK9 Monoclonal Antibody) from 14 Randomized Trials
creatorJones, Peter H ; Bays, Harold E ; Chaudhari, Umesh ; Pordy, Robert ; Lorenzato, Christelle ; Miller, Kathryn ; Robinson, Jennifer G
creatorcontribJones, Peter H ; Bays, Harold E ; Chaudhari, Umesh ; Pordy, Robert ; Lorenzato, Christelle ; Miller, Kathryn ; Robinson, Jennifer G
descriptionPrevious individual trials of alirocumab (a PCSK9 monoclonal antibody) showed significant low-density lipoprotein cholesterol reductions with overall treatment-emergent adverse event (TEAE) rates comparable with controls. This analysis evaluated safety data from 14 trials (4 phase 2 and 10 phase 3, 8 to 104 weeks; n = 5,234), in 2 pools according to control (placebo/ezetimibe). Overall, 3,340 patients received alirocumab (4,029 patient-years' exposure), 1,276 received placebo, and 618 received ezetimibe. Incidence of deaths, serious TEAEs, discontinuations because of TEAEs, and overall TEAEs were similar between alirocumab and control groups. Alirocumab was associated with a higher incidence of local injection site reactions (7.4% vs 5.3% with placebo; 3.1% vs 2.3% with ezetimibe), pruritus (1.3% vs 0.4% placebo; 0.9% vs 0.5% ezetimibe), and upper respiratory tract infection signs and symptoms (2.1% vs 1.1% placebo; 1.3% vs 0.8% ezetimibe). Incidence of musculoskeletal, neurologic, neurocognitive, ophthalmologic, hepatic events, and TEAEs related to diabetes/diabetes complications was similar between alirocumab and control groups. In a prespecified analysis of phase 3 studies, adjudicated major adverse cardiovascular events (coronary heart disease death, nonfatal myocardial infarction, ischemic stroke, and unstable angina requiring hospitalization) occurred in 1.8% alirocumab versus 2.6% placebo patients (hazard ratio 0.69, 95% confidence interval 0.43 to 1.11) and 2.8% alirocumab versus 1.5% ezetimibe patients (hazard ratio 1.4, 95% confidence interval 0.65 to 3.02). In conclusion, pooled safety data from 14 trials demonstrate that alirocumab is generally well tolerated with a favorable safety profile.
identifier
0ISSN: 0002-9149
1EISSN: 1879-1913
2DOI: 10.1016/j.amjcard.2016.08.072
3PMID: 27729106
4CODEN: AJCDAG
languageeng
publisherUnited States: Elsevier Inc
subjectAbridged Index Medicus ; Acute Coronary Syndrome - epidemiology ; Aged ; Analysis ; Angina, Unstable - epidemiology ; Antibodies, Monoclonal - adverse effects ; Anticholesteremic Agents - adverse effects ; Antilipemic agents ; Atherosclerosis ; Back Pain - chemically induced ; Cardiology ; Cardiovascular Medicine ; Clinical Trials, Phase II as Topic ; Clinical Trials, Phase III as Topic ; Comorbidity ; Confidence intervals ; Coronary Disease - epidemiology ; Coronary heart disease ; Diabetes ; Diabetes Mellitus, Type 2 - epidemiology ; Drug dosages ; Ezetimibe - adverse effects ; FDA approval ; Health aspects ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use ; Hypercholesterolemia - drug therapy ; Hypercholesterolemia - epidemiology ; Influenza, Human - chemically induced ; Low density lipoproteins ; Medical colleges ; Middle Aged ; Monoclonal antibodies ; Myocardial Infarction - epidemiology ; Nasopharyngitis - chemically induced ; Patients ; Pruritus ; Pruritus - chemically induced ; Randomized Controlled Trials as Topic ; Respiratory Tract Infections - chemically induced ; Stroke (Disease) ; Stroke - epidemiology ; Studies ; Urinary Tract Infections - chemically induced
ispartofThe American Journal of Cardiology, 2016-12-15, Vol.118 (12), p.1805-1811
rights
02016 The Author(s)
1Copyright © 2016 The Author(s). Published by Elsevier Inc. All rights reserved.
2COPYRIGHT 2016 Elsevier B.V.
3Copyright Elsevier Limited Dec 15, 2016
lds50peer_reviewed
oafree_for_read
citedbyFETCH-LOGICAL-1579t-8a1f695601056a5ce056b35ff94935b9e5fbcd5d54ba7bf65149b8d7608e3d330
citesFETCH-LOGICAL-1579t-8a1f695601056a5ce056b35ff94935b9e5fbcd5d54ba7bf65149b8d7608e3d330
links
openurl$$Topenurl_article
thumbnail$$Usyndetics_thumb_exl
backlink$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27729106$$D View this record in MEDLINE/PubMed
search
creatorcontrib
0Jones, Peter H
1Bays, Harold E
2Chaudhari, Umesh
3Pordy, Robert
4Lorenzato, Christelle
5Miller, Kathryn
6Robinson, Jennifer G
title
0Safety of Alirocumab (A PCSK9 Monoclonal Antibody) from 14 Randomized Trials
1The American Journal of Cardiology
addtitleAm J Cardiol
descriptionPrevious individual trials of alirocumab (a PCSK9 monoclonal antibody) showed significant low-density lipoprotein cholesterol reductions with overall treatment-emergent adverse event (TEAE) rates comparable with controls. This analysis evaluated safety data from 14 trials (4 phase 2 and 10 phase 3, 8 to 104 weeks; n = 5,234), in 2 pools according to control (placebo/ezetimibe). Overall, 3,340 patients received alirocumab (4,029 patient-years' exposure), 1,276 received placebo, and 618 received ezetimibe. Incidence of deaths, serious TEAEs, discontinuations because of TEAEs, and overall TEAEs were similar between alirocumab and control groups. Alirocumab was associated with a higher incidence of local injection site reactions (7.4% vs 5.3% with placebo; 3.1% vs 2.3% with ezetimibe), pruritus (1.3% vs 0.4% placebo; 0.9% vs 0.5% ezetimibe), and upper respiratory tract infection signs and symptoms (2.1% vs 1.1% placebo; 1.3% vs 0.8% ezetimibe). Incidence of musculoskeletal, neurologic, neurocognitive, ophthalmologic, hepatic events, and TEAEs related to diabetes/diabetes complications was similar between alirocumab and control groups. In a prespecified analysis of phase 3 studies, adjudicated major adverse cardiovascular events (coronary heart disease death, nonfatal myocardial infarction, ischemic stroke, and unstable angina requiring hospitalization) occurred in 1.8% alirocumab versus 2.6% placebo patients (hazard ratio 0.69, 95% confidence interval 0.43 to 1.11) and 2.8% alirocumab versus 1.5% ezetimibe patients (hazard ratio 1.4, 95% confidence interval 0.65 to 3.02). In conclusion, pooled safety data from 14 trials demonstrate that alirocumab is generally well tolerated with a favorable safety profile.
subject
0Abridged Index Medicus
1Acute Coronary Syndrome - epidemiology
2Aged
3Analysis
4Angina, Unstable - epidemiology
5Antibodies, Monoclonal - adverse effects
6Anticholesteremic Agents - adverse effects
7Antilipemic agents
8Atherosclerosis
9Back Pain - chemically induced
10Cardiology
11Cardiovascular Medicine
12Clinical Trials, Phase II as Topic
13Clinical Trials, Phase III as Topic
14Comorbidity
15Confidence intervals
16Coronary Disease - epidemiology
17Coronary heart disease
18Diabetes
19Diabetes Mellitus, Type 2 - epidemiology
20Drug dosages
21Ezetimibe - adverse effects
22FDA approval
23Health aspects
24Humans
25Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use
26Hypercholesterolemia - drug therapy
27Hypercholesterolemia - epidemiology
28Influenza, Human - chemically induced
29Low density lipoproteins
30Medical colleges
31Middle Aged
32Monoclonal antibodies
33Myocardial Infarction - epidemiology
34Nasopharyngitis - chemically induced
35Patients
36Pruritus
37Pruritus - chemically induced
38Randomized Controlled Trials as Topic
39Respiratory Tract Infections - chemically induced
40Stroke (Disease)
41Stroke - epidemiology
42Studies
43Urinary Tract Infections - chemically induced
issn
00002-9149
11879-1913
fulltextfalse
rsrctypearticle
creationdate2016
recordtypearticle
recordideNqNkk1v1DAQhiMEotvCTwBF4lIOGzxJ7NjigFYrPioWgWg5W_4YI68Se-tkkZZfX0e79NBLkQ-jsd730Yz9FsUrIBUQYO-2lRq2RiVb1bmtCK9IVz8pFsA7sQQBzdNiQQiplwJacVacj-M2twCUPS_O6q6rBRC2KDbXyuF0KKMrV71P0ewHpcvLVfljff1VlN9iiKaPQfXlKkxeR3t4W7oUhxLa8qcKNg7-L9ryJnnVjy-KZy4XfHmqF8WvTx9v1l-Wm--fr9arzRJoJ6YlV-CYoIwAoUxRg7nohjonWtFQLZA6bSy1tNWq047RvIHmtmOEY2ObhlwUV0du3GFQPqHcJT-odJBReWkDTlKrEXMnrRCMWE0NMK2YnhG0zUQujACKLLMuj6xdird7HCc5-NFg36uAcT9K4JR0nDQN_Ie0oS2pOZ8nfPNAuo37lJ9xVrVd2zAAkVXVUfVb9Sh9cHFKyuRjcfAmBnQ-36_aruYtsHrG0qPBpDiOCd394kDkHAu5ladYyDkWknCZY5F9r0_j7PWA9t71LwdZ8P4B2PhJTT6GPJHvH8V_OLoxf_ofj0mOxmMwaPPfmEna6B8h3AFW6dn2
startdate20161215
enddate20161215
creator
0Jones, Peter H
1Bays, Harold E
2Chaudhari, Umesh
3Pordy, Robert
4Lorenzato, Christelle
5Miller, Kathryn
6Robinson, Jennifer G
general
0Elsevier Inc
1Elsevier B.V
2Elsevier Limited
3Elsevier BV
scope
06I.
1AAFTH
2CGR
3CUY
4CVF
5ECM
6EIF
7NPM
8AAYXX
9CITATION
10BSHEE
113V.
127QO
137RV
147TS
157X7
167XB
1788E
188FD
198FI
208FJ
218FK
228G5
23ABUWG
24AZQEC
25BENPR
26DWQXO
27FR3
28FYUFA
29GHDGH
30GNUQQ
31GUQSH
32K9.
33KB0
34M0S
35M1P
36M2O
37MBDVC
38NAPCQ
39P64
40PADUT
41PQEST
42PQQKQ
43PQUKI
44PRINS
45Q9U
467X8
47BOBZL
48CLFQK
sort
creationdate20161215
titleSafety of Alirocumab (A PCSK9 Monoclonal Antibody) from 14 Randomized Trials
authorJones, Peter H ; Bays, Harold E ; Chaudhari, Umesh ; Pordy, Robert ; Lorenzato, Christelle ; Miller, Kathryn ; Robinson, Jennifer G
facets
frbrtype5
frbrgroupidcdi_FETCH-LOGICAL-1579t-8a1f695601056a5ce056b35ff94935b9e5fbcd5d54ba7bf65149b8d7608e3d330
rsrctypearticles
prefilterarticles
languageeng
creationdate2016
topic
0Abridged Index Medicus
1Acute Coronary Syndrome - epidemiology
2Aged
3Analysis
4Angina, Unstable - epidemiology
5Antibodies, Monoclonal - adverse effects
6Anticholesteremic Agents - adverse effects
7Antilipemic agents
8Atherosclerosis
9Back Pain - chemically induced
10Cardiology
11Cardiovascular Medicine
12Clinical Trials, Phase II as Topic
13Clinical Trials, Phase III as Topic
14Comorbidity
15Confidence intervals
16Coronary Disease - epidemiology
17Coronary heart disease
18Diabetes
19Diabetes Mellitus, Type 2 - epidemiology
20Drug dosages
21Ezetimibe - adverse effects
22FDA approval
23Health aspects
24Humans
25Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use
26Hypercholesterolemia - drug therapy
27Hypercholesterolemia - epidemiology
28Influenza, Human - chemically induced
29Low density lipoproteins
30Medical colleges
31Middle Aged
32Monoclonal antibodies
33Myocardial Infarction - epidemiology
34Nasopharyngitis - chemically induced
35Patients
36Pruritus
37Pruritus - chemically induced
38Randomized Controlled Trials as Topic
39Respiratory Tract Infections - chemically induced
40Stroke (Disease)
41Stroke - epidemiology
42Studies
43Urinary Tract Infections - chemically induced
toplevelpeer_reviewed
creatorcontrib
0Jones, Peter H
1Bays, Harold E
2Chaudhari, Umesh
3Pordy, Robert
4Lorenzato, Christelle
5Miller, Kathryn
6Robinson, Jennifer G
collection
0ScienceDirect Open Access Titles
1Elsevier:ScienceDirect:Open Access
2Medline
3MEDLINE
4MEDLINE (Ovid)
5MEDLINE
6MEDLINE
7PubMed
8CrossRef
9Academic OneFile (A&I only)
10ProQuest Central (Corporate)
11Biotechnology Research Abstracts
12Nursing & Allied Health Database
13Physical Education Index
14Health & Medical Collection
15ProQuest Central (purchase pre-March 2016)
16Medical Database (Alumni Edition)
17Technology Research Database
18Hospital Premium Collection
19Hospital Premium Collection (Alumni Edition)
20ProQuest Central (Alumni) (purchase pre-March 2016)
21Research Library (Alumni Edition)
22ProQuest Central (Alumni Edition)
23ProQuest Central Essentials
24ProQuest Central
25ProQuest Central Korea
26Engineering Research Database
27Health Research Premium Collection
28Health Research Premium Collection (Alumni)
29ProQuest Central Student
30Research Library Prep
31ProQuest Health & Medical Complete (Alumni)
32Nursing & Allied Health Database (Alumni Edition)
33Health & Medical Collection (Alumni Edition)
34Medical Database
35Research Library
36Research Library (Corporate)
37Nursing & Allied Health Premium
38Biotechnology and BioEngineering Abstracts
39Research Library China
40ProQuest One Academic Eastern Edition
41ProQuest One Academic
42ProQuest One Academic UKI Edition
43ProQuest Central China
44ProQuest Central Basic
45MEDLINE - Academic
46OpenAIRE (Open Access)
47OpenAIRE
jtitleThe American Journal of Cardiology
delivery
delcategoryRemote Search Resource
fulltextno_fulltext
addata
au
0Jones, Peter H
1Bays, Harold E
2Chaudhari, Umesh
3Pordy, Robert
4Lorenzato, Christelle
5Miller, Kathryn
6Robinson, Jennifer G
formatjournal
genrearticle
ristypeJOUR
atitleSafety of Alirocumab (A PCSK9 Monoclonal Antibody) from 14 Randomized Trials
jtitleThe American Journal of Cardiology
addtitleAm J Cardiol
date2016-12-15
risdate2016
volume118
issue12
spage1805
epage1811
pages1805-1811
issn0002-9149
eissn1879-1913
codenAJCDAG
abstractPrevious individual trials of alirocumab (a PCSK9 monoclonal antibody) showed significant low-density lipoprotein cholesterol reductions with overall treatment-emergent adverse event (TEAE) rates comparable with controls. This analysis evaluated safety data from 14 trials (4 phase 2 and 10 phase 3, 8 to 104 weeks; n = 5,234), in 2 pools according to control (placebo/ezetimibe). Overall, 3,340 patients received alirocumab (4,029 patient-years' exposure), 1,276 received placebo, and 618 received ezetimibe. Incidence of deaths, serious TEAEs, discontinuations because of TEAEs, and overall TEAEs were similar between alirocumab and control groups. Alirocumab was associated with a higher incidence of local injection site reactions (7.4% vs 5.3% with placebo; 3.1% vs 2.3% with ezetimibe), pruritus (1.3% vs 0.4% placebo; 0.9% vs 0.5% ezetimibe), and upper respiratory tract infection signs and symptoms (2.1% vs 1.1% placebo; 1.3% vs 0.8% ezetimibe). Incidence of musculoskeletal, neurologic, neurocognitive, ophthalmologic, hepatic events, and TEAEs related to diabetes/diabetes complications was similar between alirocumab and control groups. In a prespecified analysis of phase 3 studies, adjudicated major adverse cardiovascular events (coronary heart disease death, nonfatal myocardial infarction, ischemic stroke, and unstable angina requiring hospitalization) occurred in 1.8% alirocumab versus 2.6% placebo patients (hazard ratio 0.69, 95% confidence interval 0.43 to 1.11) and 2.8% alirocumab versus 1.5% ezetimibe patients (hazard ratio 1.4, 95% confidence interval 0.65 to 3.02). In conclusion, pooled safety data from 14 trials demonstrate that alirocumab is generally well tolerated with a favorable safety profile.
copUnited States
pubElsevier Inc
pmid27729106
doi10.1016/j.amjcard.2016.08.072
oafree_for_read